GW&K Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$29.8M Buy
149,501
+32,069
+27% +$6.34M 0.26% 142
2025
Q4
$22.2M Buy
117,432
+85,297
+265% +$16.4M 0.19% 193
2025
Q3
$5.69M Sell
32,135
-1,296
-4% -$193K 0.05% 265
2025
Q2
$3.8M Sell
33,431
-1,427
-4% -$153K 0.03% 278
2025
Q1
$3.67M Sell
34,858
-326
-0.9% -$36.9K 0.03% 282
2024
Q4
$3.77M Sell
35,184
-2,577
-7% -$291K 0.03% 290
2024
Q3
$3.78M Sell
37,761
-1,257
-3% -$127K 0.03% 281
2024
Q2
$3.29M Sell
39,018
-747
-2% -$59.4K 0.03% 286
2024
Q1
$2.91M Sell
39,765
-15,570
-28% -$1.15M 0.03% 293
2023
Q4
$3.95M Buy
55,335
+17,905
+48% +$1.06M 0.04% 276
2023
Q3
$2.24M Sell
37,430
-678
-2% -$44.6K 0.02% 304
2023
Q2
$2.75M Sell
38,108
-750
-2% -$56.3K 0.03% 301
2023
Q1
$2.86M Buy
38,858
+8,764
+29% +$623K 0.03% 292
2022
Q4
$2.01M Sell
30,094
-18,644
-38% -$1.21M 0.02% 307
2022
Q3
$2.62M Sell
48,738
-5,219
-10% -$307K 0.03% 290
2022
Q2
$3M Sell
53,957
-1,944
-3% -$110K 0.03% 278
2022
Q1
$3.92M Buy
55,901
+15,008
+37% +$1.09M 0.04% 274
2021
Q4
$3.94M Buy
+40,893
New +$3.78M 0.03% 282

Other funds holding LGND

GW&K Investment Management's LGND Position: Q1 2026 in Review

GW&K Investment Management increased its Ligand Pharmaceuticals (LGND) stake by 27% in Q1 2026, buying an estimated $6.34M and bringing the position to 149,501 shares worth $29.8M. The position accounts for 0.26% of the portfolio, ranked #142.

GW&K Investment Management first reported a position in LGND in Q4 2021 and has held it in 18 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • GW&K Investment Management held 149,501 shares of Ligand Pharmaceuticals worth $29.8M as of Q1 2026.
  • GW&K Investment Management bought 32,069 Ligand Pharmaceuticals shares in Q1 2026, an estimated $6.34M.
  • Ligand Pharmaceuticals made up 0.26% of GW&K Investment Management's portfolio in Q1 2026, its #142 holding.
  • GW&K Investment Management first reported a position in Ligand Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on GW&K Investment Management's 13F filing for Q1 2026, filed 13 May 2026.